Collaboration between Camgenium and Cardiac Tech to enhance post-cardiac surgery outcomes using Pace-Protect technology
In a groundbreaking development, Camgenium and Cardiac Tech have collaborated to create the Pace-Protect medical device, a significant advancement in patient care following open-heart surgery. This innovative device is designed to minimise adverse events related to temporary pacemakers, addressing an unmet need for safer solutions.
Pace-Protect offers atraumatic and stable epicardial pacing, ensuring secure adherence to the epicardial tissue for extended periods (at least 14 days post-implantation). This is achieved through a bioadhesive pacing lead that reduces tissue damage and inflammation, a key improvement over traditional temporary pacing leads.
The device's innovative design offers several key benefits:
- Atraumatic implantation: The bioadhesive lead minimises tissue damage and inflammation, promoting a smoother recovery process.
- Stable and long-term pacing performance: The Pace-Protect system demonstrates effective pacing for at least 14 days, outperforming commercial leads that often fail shortly after implantation.
- Lower energy requirements: Operating at a lower capture threshold, the device preserves battery life and minimises cardiac tissue stress.
- Continuous monitoring: Real-time assessment of heart rhythm allows for prompt detection and management of cardiac irregularities.
By providing atraumatic and stable epicardial pacing with continuous cardiac monitoring and on-demand pacing support, Pace-Protect potentially lowers complications and improves cardiac function stability during the critical postoperative period.
The Pace-Protect system is the first to utilise a Soft Silicon mesh network in a clinical environment. This cutting-edge technology ensures world-class data security for patient confidentiality and high resilience, ensuring individual Pace-Protects never lose contact with the cloud.
In related news, Medtronic has received CE mark for its VitalFlow ECMO System, while Biotricity and B-Secur have launched a device-neutral ambulatory cardiac monitoring platform, and Ceryx Medical has secured $15 million to advance a groundbreaking heart failure technology.
While specific clinical outcome data for Pace-Protect are not yet available, the device's improved capture thresholds, lead stability, and continuous monitoring function strongly correlate with better recovery and lower post-surgical cardiac complications.
[1] General principles of epicardial pacing post-cardiac surgery [3] Existing pacemaker technology for context [4] Risks associated with conventional epicardial pacing during open-heart surgery
- The collaboration between Camgenium and Cardiac Tech has resulted in the creation of the Pace-Protect device, a significant advancement in digital health, aimed at improving patient care following open-heart surgery by minimising adverse events related to temporary pacemakers.
- The Pace-Protect system, pioneering the use of Soft Silicon mesh network in a clinical environment, leverages cutting-edge technology to ensure world-class data security for patient confidentiality and high resilience, improving medical-conditions management and overall health-and-wellness.
- With its innovative design, offering atraumatic implantation, stable and long-term pacing performance, lower energy requirements, continuous monitoring, and potential lower complications, the Pace-Protect device may contribute to better recovery and improved cardiovascular-health outcomes, particularly during the critical postoperative period.
